Concerns that the injectable contraceptive depotmedroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of Acquired Immune Deficiency Syndromes|
|State||Published - 2014|
All Science Journal Classification (ASJC) codes
- Infectious Diseases
- Pharmacology (medical)